No Data
Press Release Biocartis NV: Biocartis Welcomes Gina Wallar, PhD as Chief Business Officer and Judith Vacchino, PhD as VP Global Marketing
PRESS RELEASE - 10/06/2024, 07:00 CEST Biocartis Welcomes Gina Wallar, PhD as Chief Business Officer and Judith Vacchino, PhD as VP Global Marketing Mechelen, Belgium 10 June 2024 – Biocartis NV (the 'Company' or
Form 144 | NeoGenomics(NEO.US) Officer Proposes to Sell 198.34K in Common Stocks
SEC FILLINGS DISCLOSED/ May 28, $NeoGenomics(NEO.US)$ Officer BRUCE K CROWTHER intends to sell 13,882 shares of its common stock on May 28, with a total market value of approximately $198.34K. Sour
NeoGenomics Introduces Comprehensive Lung Solution & Feature Hematopathology Services At ASCO
NeoGenomics, Inc. (NASDAQ:NEO), a leading oncology testing services company, will showcase its versatile lung solution and its COMPASS Hematopathology Services portfolio at the American Society of Cli
NeoGenomics to Introduce Comprehensive Lung Solution & Feature Hematopathology Services at ASCO, Offering Actionable Insights to Support Treatment Management
NeoGenomics, Inc. (NASDAQ: NEO), a leading oncology testing services company, will showcase its versatile lung solution and its COMPASS Hematopathology Services portfolio at the American Society of Clinical Oncology (ASCO) conference in Chicago, May 31–June 4 (booth #31093).
NeoGenomics(NEO.US) Officer Sells US$16,511.26 in Common Stock
$NeoGenomics(NEO.US)$ Officer Olivo Alicia C sold 1,049 shares of common stock on May 15, 2024 at an average price of $15.74 for a total value of $16,511.26.Source: Announcement What is statement of c
Increasing Losses Over Three Years Doesn't Faze NeoGenomics (NASDAQ:NEO) Investors as Stock Rises 5.3% This Past Week
If you love investing in stocks you're bound to buy some losers. But the last three years have been particularly tough on longer term NeoGenomics, Inc. (NASDAQ:NEO) shareholders. Unfortunately, they